UDCA Dual Sourcing: What Supply Concentration Actually Costs
Share
Supply concentration in ursodeoxycholic acid is real, and a second source is a sensible response to it. The problem is that most second-source exercises do not produce a second source. They produce a second invoice from a supplier who buys the same intermediate from the same part of the world, and that leaves the underlying risk exactly where it was.
Before any of the numbers, that is the point worth carrying away: diversification is a property of the upstream chain, not of your purchase orders. Everything else in this article is detail around that claim.
How concentrated the market is, and how much to trust the figure
Commercial market reports covering this molecule converge on a picture of a small number of producers holding most of the capacity. The figures differ depending on who is counting, and the differences are large enough to be worth stating plainly rather than picking the most dramatic number.
| What the reports say | Range across sources | How to treat it |
|---|---|---|
| Share held by the largest producers | Roughly 50–80% depending on whether you count the top three, four or five, and on whether the count is API or finished product | Directional only |
| Regional share of consumption | Asia-Pacific around half, Europe around a quarter to a third | Directional only |
| Split by production route | Chemical synthesis the majority (around two thirds), enzymatic the remainder | Directional only |
| Market size and growth | Mid hundreds of millions of US dollars, growing at a high single-digit rate | Directional only |
I am deliberately not putting single figures on those lines. These numbers come from commercial reports, they are estimates rather than audited data, and the reports do not agree with each other on market definition. Anyone quoting you a precise share to two decimal places is quoting a particular report, not a fact. What survives the disagreement is the shape: a handful of producers, a large share of capacity, and a geographic tilt towards Asia.
Why concentration bites harder on this molecule than on most
Generic concentration is normal in APIs. Two features make this one worse than average.
The first is the starting material. Industrial production of ursodeoxycholic acid runs from a bile acid feedstock, much of which is recovered from poultry processing by-products. That upstream supply is itself a by-product stream, so its availability is tied to the throughput of a different industry rather than to demand for the API. A by-product stream does not expand on request. It can also be geographically clustered, which means two API sites on different continents can still be drawing from the same region.
The second is route dependence. The two broad manufacturing routes differ in yield, solvent profile and the impurity fingerprint they leave behind. That matters for sourcing because a second supplier is only a true alternative if their material clears your specification without redevelopment work. A second source whose route gives a materially different residual-solvent or elemental-impurity profile is not a drop-in replacement; it is a new qualification project, and the cost of that project belongs in the comparison. We look at the route difference properly in the companion article on chemical versus enzymatic synthesis.
The arithmetic of a second source
The commercial argument is usually made as a straight price comparison, which understates it in one direction and overstates it in another. A realistic version has three lines.
| Line | What goes in it |
|---|---|
| Premium | (second-source price − incumbent price) × the volume you actually move. This is the visible cost and the one that gets the attention. |
| Qualification cost | Analytical work on the second source's material, any additional batches, regulatory documentation and, if the route differs enough, reformulation or revalidation. One-off, but rarely small. |
| Value of the option | The avoided cost of a supply interruption, multiplied by the probability you assess for one. This is the line that never appears in the spreadsheet. |
The reason to set it out this way is that the premium is the line you can measure and the option value is the line that matters. A premium that looks indefensible in isolation is often cheap against a realistic interruption scenario, particularly for a material with a long qualification lead time of its own. The mistake in both directions is the same: treating an insurance decision as a purchasing decision.
The trap: a second source that shares a first source
Here is the check that most dual-sourcing programmes skip. Two suppliers, two contracts, two sets of documents, and no actual diversification — because both are buying the key starting material from the same place.
You will not find this out from a certificate of analysis, and you will not find it out from a website. It comes from asking directly, and from asking on the record:
- Where does the starting material come from? Not the API site — the feedstock. Country, and where possible the supplier tier.
- Is the feedstock from more than one source? A site with a single feedstock supplier is itself a single point of failure, whatever its own capacity looks like.
- What happens to your allocation if the feedstock tightens? This is a contractual question, and the answer reveals how much of the site's capacity is already committed.
- Do your two proposed sources share a feedstock region? If yes, you have redundancy against a plant failure and none against a regional disruption.
The last one is the reason to do this exercise before signing rather than after. Redundancy against the wrong risk is expensive reassurance.
What the regulatory environment is adding
Supply resilience has been moving from an operational concern to a scored criterion. EU policy work on critical medicines has been heading towards asking public buyers to weigh diversification in tenders, and the direction of travel in several markets is towards requiring evidence of a resilience plan rather than accepting an assurance. Some of this is still in progress, and the specifics have been changing, so treat it as a trend rather than a current obligation and check the position for your own market.
The reason it belongs in this article is that it changes what "a second source" has to mean on paper. If resilience is being scored, then a documented, genuinely independent second source stops being a procurement preference and starts being an asset you can point at. The same regulatory documentation that gets a material into a market increasingly travels alongside evidence about where it came from.
Five things to put in the sourcing file
- The feedstock map, not the supplier list — which region, how many tiers down you actually know.
- The route of each source, so you know whether a switch is a drop-in or a project.
- The specification comparison across both sources, on the limits that differ, not on the headline assay.
- An allocation statement from each source, in writing, covering what share of capacity is committed to you.
- An annual re-check, because a second source can quietly become a first source's customer over three years.
Our supply-chain page sets out how we approach this on the supply side, and the independent questions to put to any supplier are in the verification checklist. Requirements for a specific market and volume can be raised through a quotation request.
Frequently asked questions
Is the UDCA API market concentrated?
Yes. Commercial market reports consistently describe a small number of producers holding most of the capacity, with a geographic tilt towards Asia. The exact shares vary considerably between reports, so treat any single figure as directional.
Does having two suppliers count as dual sourcing?
Not necessarily. If both buy their key starting material from the same region or the same supplier, you have redundancy against a plant failure but not against a regional disruption.
What makes a second source genuinely independent?
A different feedstock origin, and ideally a different manufacturing route. Different commercial paperwork from the same upstream chain is not independence.
Why does the synthetic route matter for a second source?
Because the route determines residual solvents, elemental impurity profile and the impurity fingerprint. A material that differs materially may need redevelopment work before it can be used, which is a qualification cost rather than a price difference.
What does a second source cost?
Three things: the price premium on the volume you move, the one-off qualification cost, and the value of the option you are buying. Only the first appears in most comparisons, and it is the least important of the three.
Is supply-resilience evidence becoming a requirement?
It is moving that way in some markets, with EU policy work on critical medicines heading towards weighing diversification in public procurement. The specifics are still developing, so confirm the current position for your market.
The question that exposes the real position
Ask each of your suppliers one question: where does your starting material come from? If the answer from both is the same region, your supply chain is one decision wide, and the second contract is a document rather than a hedge.
The documents I would point you to are the European Medicines Agency, the European Pharmacopoeia and the peer-reviewed review of biological UDCA synthesis. Versions differ, and the details matter here.
This article discusses supply-chain structure and sourcing practice for bile-acid active substances, written for procurement and supply-chain professionals. It states no therapeutic use, dose or indication for any substance, and no order quantity or lead time, and it makes no claim about the capacity, intention or conduct of any named company. Market figures are drawn from commercial estimates that disagree with one another and should be treated as directional. Verify the current regulatory position for your own market before relying on it.